Skip to main content
HSIC logo

Henry Schein, Inc. (HSIC) Stock: Price, Forecast & Analyst Target

Henry Schein, Inc. (HSIC) — MoonshotScore 73/100 (Strong band), calculated Nov 18, 2026. Price $84.80 (-1.04%), as of the Nov 19, 2026 trading session; market cap $9.37B. Expected results Feb 23, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 50.92× (cash as of Sep 26, 2026) · expected results Feb 23, 2027

$84.80 −$0.89 (-1.04%) Market Cap $9.37B

Henry Schein, Inc. · HSIC · NASDAQ · Healthcare · Medical - Distribution

Research dated 2026-09-13: Henry Schein supplies dental and medical practices with consumables, equipment and pharmaceuticals while also selling practice software and support services. Its case rests on whether rising sales and cost initiatives can produce durable earnings and cash growth despite substantial leverage.

Price as of Nov 19, 2026

Key Statistics

73 of 100

MoonshotScore v2 · Henry Schein (HSIC)

Strong
Business Quality Solid (79)
Financial Safety Strained (29)
Valuation Fair (79)
Growth Durability Growing (66)
Momentum Surging (80)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a strained balance sheet; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.

  • quarterly revenue $3.34B (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 5 of the last 8 reports
  • Altman Z 2.75 · Piotroski F 6

Holding back: balance-sheet strain

Helping: business quality, an attractive price, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for HSIC (57 recorded, newest six shown)
RecordedScoreBand
73Strong
72Strong
72Strong
72Strong
73Strong
73Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$84.80
Change on the day-1.04%
52-week range$68.70–$92.18
Market capitalisation$9.37B—
Price / earnings (trailing)22.48
Shares traded on the day2.05M
Beta (volatility vs the S&P 500)0.86

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $63, high $90, latest $85. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $90 $63 high $90 Feb 24, 2026 · Earnings results · reported above the recorded estimate · close $821May 5, 2026 · Earnings results · reported above the recorded estimate · close $712Aug 4, 2026 · Earnings results · reported above the recorded estimate · close $883Nov 3, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $864Nov 3, 2026 · Earnings results · reported above the recorded estimate · close $865 Oct 17, 2025 Nov 19, 2026 · $85 $63Oct 17, 2025$63Oct 31, 2025$71Nov 14, 2025$75Nov 28, 2025$77Dec 12, 2025$76Dec 26, 2025$78Jan 9, 2026$77Jan 23, 2026$80Feb 6, 2026$80Feb 20, 2026$78Mar 6, 2026$72Mar 20, 2026$74Apr 2, 2026$79Apr 17, 2026$74May 1, 2026$73May 15, 2026$77May 29, 2026$81Jun 12, 2026$85Jun 26, 2026$84Jul 10, 2026$85Jul 24, 2026$88Aug 7, 2026$89Aug 21, 2026$90Sep 4, 2026$85Sep 18, 2026$85Oct 2, 2026$86Oct 16, 2026$85Oct 30, 2026$86Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • Our commitments have not changed, and we continue to expect more than $200 million of operating income improvement including a $125 million run rate by the end of 2026.

    Frederick Lowery · Statement from

  • We are therefore raising our financial guidance for the year reflecting the net benefit of tariff refunds received during the quarter targeted and limited growth investments in the fourth quarter, which will contribute to growth in 2027 and improved underlying business performance.

    Frederick Lowery · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Henry Schein (HSIC): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Moderate
Growth Durability Moderate
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Debt/Equity Negative
ROE Moderate
Gross Margin Neutral

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Henry Schein (HSIC), and what does it report?

Short answer · as of

Henry Schein is primarily a healthcare distributor, not a care provider or drug developer. Demand comes from dental professionals, laboratories, physician practices and institutions purchasing routine supplies, specialized equipment, pharmaceuticals, vaccines and related repair services.

Healthcare Distribution supplies the overwhelming share of disclosed segment revenue. Technology and Value-Added Services adds practice-management software, electronic services, infrastructure support, financing, education and consulting, giving Henry Schein a broader relationship with a practice than product delivery alone.

2 · Latest results

What do the latest results show for Henry Schein (HSIC)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $3.34B.

The latest period delivered the strongest revenue and gross profit in the quarterly series shown. Operating profit improved from the preceding period, although net income and diluted earnings softened sequentially; recent reported revenue and earnings also came in ahead of consensus.

Annual revenue has reached a high for the presented history, while net income remains well below its earlier peak. Management attributes current momentum to local-currency sales growth, stronger margins and early benefits from its value-creation program, with planned savings spanning gross-profit actions and lower administrative expense.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$3.47B Sep 26, 2026
Latest quarter · SG&A
$819.00M Sep 26, 2026
Latest quarter · FMP standardized operating result
$215.00M Sep 26, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 26, 2026$3.47BNot available$819.00M$215.00M
Jun 27, 2026$3.46BNot available$831.00M$200.00M
Mar 28, 2026$3.37BNot available$809.00M$182.00M
Dec 27, 2025$3.44BNot available$808.00M$186.00M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$3.47B Nov 3, 2026
Latest report · revenue estimate
$3.48B Nov 3, 2026
Latest report · revenue vs estimate
Below estimate Nov 3, 2026
Latest report · EPS vs estimate
Above estimate Nov 3, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 3, 2026$3.47B$3.48B$1.3700$1.3600
Aug 4, 2026$3.46B$3.37B$1.2700$1.2400
May 5, 2026$3.37B$3.34B$1.3200$1.2000
Feb 24, 2026$3.44B$3.35B$1.3400$1.3000
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$3.34B$101M$0.84 (diluted)
Q4 FY2025$3.44B$101M$0.85 (diluted)
Q1 FY2026$3.37B$107M$0.92 (diluted)
Q2 FY2026$3.46B$94M$0.82 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Henry Schein (HSIC)?

Short answer

Cash and short-term investments were $184.00M at the Sep 26, 2026 balance-sheet date. Operating cash flow was $161.00M for the quarter ended Sep 26, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Operating cash flow rebounded sharply after turning negative in the preceding period, and the cash balance recovered. Cash generation has nevertheless varied considerably across periods, so reported profit has not translated into a smooth stream of internally generated funds.

Debt stands far above cash and short-term investments. Current assets cover current liabilities on the reported measure, yet the quicker liquidity measure falls short when less-liquid current assets are excluded; for a distribution-heavy business, weak conversion of inventory and receivables would therefore reduce financial flexibility quickly.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$161.00M Sep 26, 2026
Previous quarter · operating cash flow
$242.00M Jun 27, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 26, 2026$161.00M−$30.00M
Jun 27, 2026$242.00M−$46.00M
Mar 28, 2026−$97.00M−$39.00M
Dec 27, 2025$381.00M−$43.00M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Henry Schein (HSIC)?

Short answer · as of

The next earnings report is expected on Feb 23, 2027.

Upcoming results need to preserve the recent sales momentum while converting more gross profit into operating income and cash. Selling and administrative expense has risen alongside gross profit, making expense discipline as important as product demand.

Management expects labor efficiencies to begin contributing and says its improvement program will draw from gross-profit initiatives as well as administrative savings. Consensus assumes continued revenue and earnings growth across the forecast horizon, so progress against those operating commitments will matter more than another isolated earnings beat.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. Home solutions continue to deliver double digit growth And looking forward, we expect an early 2027 US flu season.

    Frederick Lowery ·

  2. We continue to expect than $200 million of operating income improvement including a $125 million run rate by the end of 2026.

    Ronald N. South ·

2 more statements are quoted under Upcoming events

What the records here don't tell us

  • The newest quarter held here (Q3 FY2025) was filed Nov 4, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Henry Schein compare with its peers?

Short answer

Henry Schein's score ranks 8th of 10 in the bounded comparison shown, against 9 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Henry Schein sits between a conventional healthcare distributor and a practice-technology vendor. A pure distributor may deliver supplies and equipment, while Henry Schein can also provide software, electronic services, technical infrastructure, financing, repairs and consulting within the same customer relationship.

That breadth does not make Henry Schein primarily a software company: Healthcare Distribution accounts for the overwhelming share of disclosed segment revenue. Its economics therefore remain closely tied to product volume, mix and cash conversion, with technology and services serving as a differentiating extension rather than the main revenue engine.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Guardian Pharmacy Services, Inc. (GRDN) Same industry, near in market value$46.66 Nov 19, 2026$2.96B96 5-pillar Nov 18, 2026
Globus Medical, Inc. (GMED) Named competitor$70.53 Nov 18, 2026$9.34B94 5-pillar Nov 18, 2026
McKesson Corporation (MCK) Same industry, near in market value$1062.16 Nov 19, 2026$123B92 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Same industry, near in market value$272.37 Nov 19, 2026$63.0B88 5-pillar Nov 18, 2026
Cencora, Inc. (COR) Same industry, near in market value$341.25 Nov 19, 2026$65.1B86 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Named competitor$140.34 Nov 19, 2026$8.90B77 5-pillar Nov 18, 2026
DaVita Inc. (DVA) Named competitor$156.24 Nov 19, 2026$9.83B76 5-pillar Nov 18, 2026
Henry Schein (HSIC) — this page$84.80$9.37B73
Molina Healthcare, Inc. (MOH) Named competitor$203.34 Nov 19, 2026$10.6B68 5-pillar Nov 18, 2026
Prestige Consumer Healthcare Inc. (PBH) Same industry, near in market value$49.60 Nov 19, 2026$2.35B63 5-pillar Nov 18, 2026
Masimo Corporation (MASI) Named competitor$179.95 Aug 21, 2026$9.42B— Model unavailable

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$85.00 – $110.00
Consensus target
$97.14
Median target
$95.00

Consensus record · Captured .

Measured against a quoted price of $84.80 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 8, 2026

Transactions
4
Identified insiders
3
Purchases
0
Sales
0
Other transactions
4

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
597 Period end Sep 30, 2026
Previous quarter · holders
579 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Kohlberg Kravis Roberts & Co. L.P.15,652,032
Fmr LLC7,716,551
Blackrock, INC.7,057,010
Vanguard Capital Management LLC6,252,136
Artisan Partners Limited Partnership5,505,566

Tracked investors

Which of the 16 named investors we follow held HSIC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported HSIC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Henry Schein (HSIC)?

Read these with our analysis →

What Investors Ask About Henry Schein (HSIC) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What does Henry Schein sell to dental practices and laboratories?

Henry Schein supplies consumables, infection-control products, restorative materials, instruments, chairs, imaging systems and digital restoration equipment, alongside repair and practice-support services.

Why is Henry Schein more than a medical-products distributor?

Its Technology and Value-Added Services operation provides practice-management software, electronic services, infrastructure support, financing, education and consulting. Those offerings extend the customer relationship beyond purchasing physical supplies.

How are Henry Schein’s value-creation initiatives meant to improve profit?

Management expects the program to combine gross-profit improvements with administrative savings, including labor efficiencies. Recent gross profit and operating profit have improved, but sustained cash conversion would provide stronger confirmation that those benefits are taking hold.

Why can Henry Schein report profit while operating cash flow swings?

Net income remained positive throughout the periods shown, while operating cash flow ranged from negative to sharply positive. That divergence makes conversion of accounting profit into cash a critical measure of financial flexibility given the debt load.

What is the HSIC stock price today?

The last price recorded for Henry Schein, Inc. (HSIC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the HSIC price target?

The analyst consensus price target for Henry Schein, Inc. (HSIC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 75 figures on this page — 2 from SEC filings and earnings calls, 66 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is Henry Schein (HSIC), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment
  • 2. What do the latest results show for Henry Schein (HSIC)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Henry Schein (HSIC)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set
  • 4. What should you watch next at Henry Schein (HSIC)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts; Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters
  • 5. How does Henry Schein compare with its peers?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: What does Henry Schein sell to dental practices and laboratories?: Business description
  • FAQ: Why is Henry Schein more than a medical-products distributor?: Business description; Revenue by segment
  • FAQ: How are Henry Schein’s value-creation initiatives meant to improve profit?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • FAQ: Why can Henry Schein report profit while operating cash flow swings?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash against market value
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.